Drugs / EP0057
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02769962 | May 2016 → Apr 2023 | prostate cancer, small cell lung carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05411679 | Apr 2023 → Aug 2024 | gastric cancer, small cell lung carcinoma | Ellipses Pharma | Withdrawn | No outcome recorded |
| Phase 2 | NCT04669002 | Dec 2020 → Feb 2023 | ovarian cancer | Ellipses Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP0057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04669002 ↗ |
| Modality | Other / unclassified | “EP0057 (formerly CRLX101) is a nanoparticle drug conjugate composed of 20 (S)-camptothecin” NCT02769962 ↗ |
| Route | Intravenous | “EP0057 (formerly CRLX101) intravenous (IV) every (Q) 2weeks Day 1 and Day 15” NCT02769962 ↗ |